Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Complete Genomics, Inc. (GNOM) Going to Reward These Hedge Funds?

Page 1 of 2

Complete Genomics, Inc. (NASDAQ:GNOM)Complete Genomics, Inc. (NASDAQ:GNOM) was in 9 hedge funds’ portfolio at the end of the fourth quarter of 2012. GNOM investors should pay attention to an increase in activity from the world’s largest hedge funds lately. There were 7 hedge funds in our database with GNOM positions at the end of the previous quarter.

In the financial world, there are many metrics market participants can use to analyze their holdings. A couple of the most useful are hedge fund and insider trading movement. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best investment managers can trounce the S&P 500 by a superb margin (see just how much).

Equally as integral, positive insider trading sentiment is another way to break down the world of equities. Obviously, there are a variety of stimuli for an insider to sell shares of his or her company, but just one, very simple reason why they would behave bullishly. Various academic studies have demonstrated the valuable potential of this tactic if investors know what to do (learn more here).

Now, it’s important to take a gander at the latest action surrounding Complete Genomics, Inc. (NASDAQ:GNOM).

How have hedgies been trading Complete Genomics, Inc. (NASDAQ:GNOM)?

At the end of the fourth quarter, a total of 9 of the hedge funds we track were long in this stock, a change of 29% from the third quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few notable hedge fund managers who were increasing their stakes significantly.

When looking at the hedgies we track, Cliff Asness’s AQR Capital Management had the most valuable position in Complete Genomics, Inc. (NASDAQ:GNOM), worth close to $7.7 million, accounting for less than 0.1%% of its total 13F portfolio. Coming in second is Carl Tiedemann and Michael Tiedemann of TIG Advisors, with a $3.8 million position; 0.7% of its 13F portfolio is allocated to the company. Some other peers with similar optimism include Jean-Marie Eveillard’s First Eagle Investment Management, James Dondero’s Highland Capital Management and Kerr Neilson’s Platinum Asset Management.

As aggregate interest increased, some big names have jumped into Complete Genomics, Inc. (NASDAQ:GNOM) headfirst. TIG Advisors, managed by Carl Tiedemann and Michael Tiedemann, initiated the most outsized position in Complete Genomics, Inc. (NASDAQ:GNOM). TIG Advisors had 3.8 million invested in the company at the end of the quarter. Jean-Marie Eveillard’s First Eagle Investment Management also made a $3.6 million investment in the stock during the quarter. The following funds were also among the new GNOM investors: Israel Englander’s Millennium Management, Jacob Gottlieb’s Visium Asset Management, and D. E. Shaw’s D E Shaw.

Insider trading activity in Complete Genomics, Inc. (NASDAQ:GNOM)

Bullish insider trading is most useful when the primary stock in question has seen transactions within the past half-year. Over the latest half-year time period, Complete Genomics, Inc. (NASDAQ:GNOM) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

Let’s also examine hedge fund and insider activity in other stocks similar to Complete Genomics, Inc. (NASDAQ:GNOM). These stocks are Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Omeros Corporation (NASDAQ:OMER), Inovio Pharmaceuticals Inc (NYSEAMEX:INO), and BioSpecifics Technologies Corp. (NASDAQ:BSTC). This group of stocks are the members of the biotechnology industry and their market caps resemble GNOM’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!